Immune cell army takes on advanced melanoma in new trial
NCT ID NCT07310784
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new treatment called LM103 TILs, made from a patient's own immune cells, for advanced melanoma that hasn't responded to standard therapies. About 92 adults will be randomly assigned to receive either the TIL therapy or standard care. The study aims to see if this approach can slow cancer growth and improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
-
Beijing Go Broad Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, China
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, Guangxi, China
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, Jiangsu, China
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, Guangxi, China
-
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi’an, Shanxi, China
-
The Third People's Hospital of Zhengzhou
RECRUITINGZhengzhou, Henan, China
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic drug shrink advanced melanoma tumors?
- Engineered immune cells take aim at Hard-to-Treat cancers
- Could a diabetes drug boost immunotherapy in advanced melanoma?
- New combo therapy takes on advanced cancers
- Wheat germ supplement studied for immune boost in advanced cancer
- Could a common diabetes drug boost immunotherapy in Hard-to-Treat cancers?